Eisai Co., Ltd. (TYO:4523)
Japan
· Delayed Price · Currency is JPY
4,621.00
-14.00 (-0.30%)
Jan 31, 2025, 3:30 PM JST
Eisai Revenue
Eisai had revenue of 195.99B JPY in the quarter ending September 30, 2024, with 10.97% growth. This brings the company's revenue in the last twelve months to 753.22B, down -0.80% year-over-year. In the fiscal year ending March 31, 2024, Eisai had annual revenue of 741.75B, down -0.36%.
Revenue (ttm)
753.22B
Revenue Growth
-0.80%
P/S Ratio
1.75
Revenue / Employee
68.06M
Employees
11,067
Market Cap
1,302.61B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2024 | 741.75B | -2.65B | -0.36% |
Mar 31, 2023 | 744.40B | -11.82B | -1.56% |
Mar 31, 2022 | 756.23B | 110.28B | 17.07% |
Mar 31, 2021 | 645.94B | -49.68B | -7.14% |
Mar 31, 2020 | 695.62B | 52.79B | 8.21% |
Mar 31, 2019 | Pro | Pro | Pro |
Mar 31, 2018 | Pro | Pro | Pro |
Mar 31, 2017 | Pro | Pro | Pro |
Mar 31, 2016 | Pro | Pro | Pro |
Mar 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Chugai Pharmaceutical | 1,170.61B |
Daiichi Sankyo Company | 1,758.07B |
HOYA Corporation | 812.74B |
Takeda Pharmaceutical Company | 4,546.08B |
Terumo | 986.67B |
Otsuka Holdings | 2,269.56B |
Astellas Pharma | 1,772.16B |
Olympus | 973.60B |
Eisai News
- 1 day ago - Europe to review safety data for Eisai-Biogen Alzheimer's drug - Reuters
- 5 days ago - FDA approves IV maintenance dosing of Leqembi® (lecanemab-irmb) for the treatment of early Alzheimer's Disease in the US - Benzinga
- 5 days ago - US FDA OKs monthly maintenance dosing for Eisai/Biogen's Alzheimer's drug - Reuters
- 5 days ago - FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease - PRNewsWire
- 7 days ago - Merck/Eisai's Keytruda Plus Lenvima Regime Shows Mixed Data In Esophagus Cancer Study - Benzinga
- 8 days ago - Merck, Eisai post mixed Phase 3 data for Keytruda/ Lenvima in GIT cancer - Seeking Alpha
- 8 days ago - Merck and Eisai's cancer drugs fail to improve overall survival in late-stage trial - Reuters
- 9 days ago - Biogen partner Eisai reportedly sees FY25 launch for home version of Alzheimer’s drug - Seeking Alpha